Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 5, 2015

Primary Completion Date

November 20, 2017

Study Completion Date

November 20, 2017

Conditions

Myelofibrosis

Interventions

DRUG

Idelalisib

Idelalisib tablets administered orally for 24 weeks

DRUG

Ruxolitinib

Ruxolitinib will be administered per standard of care according to package insert

Trial Locations (2)

University of Michigan Health System, Ann Arbor

Stanford Hospital and Clinics, Stanford